The Role of beta-Adrenergic Overstimulation in the Early Stages of Renal Injury

Imagem de Miniatura
Arquivos
art_PONTE_The_Role_of_betaAdrenergic_Overstimulation_in_the_Early_2017.PDF (1.9 MB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Autores
PONTE, Mariana Charleaux de
CASARE, Fernando Augusto Malavazzi
COSTA-PESSOA, Juliana Martins
CARDOSO, Vanessa Gerolde
MALNIC, Gerhard
MELLO-AIRES, Margarida
OLIVEIRA-SOUZA, Maria
Citação
KIDNEY & BLOOD PRESSURE RESEARCH, v.42, n.6, p.1277-1289, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background/Aims: To assess the possible contribution of the beta-adrenergic overstimulation in early stages of renal injury, the present study evaluated, in rats, the effects of the beta-adrenoceptor agonist isoproterenol (ISO) on renal function and morphology, as well as the renal mRNA and protein expression of the NADPH oxidase isoform 4 (Nox 4) and subunit p22(phox), endoplasmic reticulum (ER) stress, pro-inflammatory, pro-apoptotic and renin-angiotensin system (RAS) components. Methods: Wistar rats received ISO (0.3 mg.kg(-1).day(-1) s.c.) or vehicle (control) for eight days. At the end of the treatment, food and water intake, urine output and body weight gain were evaluated and renal function studies were performed. Renal tissue was used for the morphological, quantitative PCR and immunohistochemical studies. Results: ISO did not change metabolic parameters or urine output. However it induced a decrease in renal blood flow and an increase in the filtration fraction. These changes were accompanied by increased cortical mRNA and protein expression for the renal oxidative stress components including Nox 4 and p22(phox); ER stress, pro-inflamatory, pro-apoptotic as well as RAS components. ISO also induced a significant increase in medullar renin protein expression. Conclusion: These findings support relevant information regarding the contribution of specific beta-adrenergic hyperactivity in early stage of renal injury, indicating the reactive oxygen species, ER stress and intrarenal RAS as important factors in this process. (c) 2017 The Author(s) Published by S. Karger AG, Basel
Palavras-chave
Isoproterenol, beta-adrenergic stimulation, Renal hemodynamics, Oxidative stress, Inflammation, Intrarenal renin-angiotensin system
URI
https://observatorio.fm.usp.br/handle/OPI/25840
Referências
  1. Abdel-Sayed S, 2003, AM J HYPERTENS, V16, P515, DOI 10.1016/S0895-7061(03)00903-8
  2. Ahmed R, 2017, EVID-BASED COMPL ALT, DOI 10.1155/2017/5370545
  3. ALHENCGELAS F, 1989, J HYPERTENS, V7, pS9, DOI 10.1097/00004872-198909007-00003
  4. Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080
  5. Bidani AK, 2009, HYPERTENSION, V54, P393, DOI 10.1161/HYPERTENSIONAHA.109.133777
  6. Boivin V, 2001, KIDNEY INT, V59, P515, DOI 10.1046/j.1523-1755.2001.059002515.x
  7. Brembilla-Perrot B, 2005, EUROPACE, V7, P621, DOI 10.1016/j.eupc.2005.06.012
  8. Chan JSD, 2000, MOL CELL BIOCHEM, V212, P73, DOI 10.1023/A:1007152821315
  9. Cupples WA, 2007, AM J PHYSIOL-RENAL, V292, pF1105, DOI 10.1152/ajprenal.00194.2006
  10. Dalal S, 2012, MOL CELL BIOCHEM, V364, P59, DOI 10.1007/s11010-011-1205-7
  11. Davel APC, 2008, AM J PHYSIOL-HEART C, V295, pH211, DOI 10.1152/ajpheart.00581.2007
  12. Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004
  13. DiBona GF, 1997, PHYSIOL REV, V77, P75
  14. Dobrovolskaia MA, 2005, CURR CANCER DRUG TAR, V5, P325, DOI 10.2174/1568009054629645
  15. EMORI T, 1991, HYPERTENSION, V18, P165, DOI 10.1161/01.HYP.18.2.165
  16. Fu YC, 2004, CARDIOVASC RES, V62, P558, DOI 10.1016/j.cardiores.2004.01.039
  17. Guijarro C, 2001, KIDNEY INT, V59, P415, DOI 10.1046/j.1523-1755.2001.059002415.x
  18. Johns EJ, 2011, COMPR PHYSIOL, V1, P731, DOI 10.1002/cphy.c100043
  19. Kao MPC, 2010, J HUM HYPERTENS, V24, P1, DOI 10.1038/jhh.2009.70
  20. Kobori H, 2001, J AM SOC NEPHROL, V12, P431
  21. KON V, 1989, MINER ELECTROL METAB, V15, P33
  22. Casare FAM, 2016, AM J PHYSIOL-RENAL, V310, pF1295, DOI 10.1152/ajprenal.00471.2015
  23. Malpas SC, 2010, PHYSIOL REV, V90, P513, DOI 10.1152/physrev.00007.2009
  24. Mohamed SS, 2015, BIOCHEM PHARMACOL, V98, P403, DOI 10.1016/j.bcp.2015.10.004
  25. Moniri NH, 2007, BIOCHEM PHARMACOL, V74, P64, DOI 10.1016/j.bcp.2007.01.016
  26. Navar LG, 2001, J RENIN-ANGIO-ALDO S, V2, pS176, DOI 10.1177/14703203010020013001
  27. Nirmala C, 1996, MOL CELL BIOCHEM, V159, P85, DOI 10.1007/BF00420910
  28. Oliveira-Souza M, 2002, KIDNEY INT, V62, P1693, DOI 10.1046/j.1523-1755.2002.00604.x
  29. OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
  30. Ruster C, 2006, J AM SOC NEPHROL, V17, P2985, DOI 10.1681/ASN.2006040356
  31. Schlaich MP, 2009, J AM SOC NEPHROL, V20, P933, DOI 10.1681/ASN.2008040402
  32. Schonthal A.H., 2012, SCIENTIFICA, DOI 10.6064/2012/857516)
  33. Shimizu MHM, 2013, EXP GERONTOL, V48, P298, DOI 10.1016/j.exger.2012.11.006
  34. SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827
  35. Taniguchi M, 2015, CURR OPIN NEPHROL HY, V24, P345, DOI 10.1097/MNH.0000000000000141
  36. Thieme K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122265
  37. Wang TT, 1998, KIDNEY INT, V54, P785, DOI 10.1046/j.1523-1755.1998.00069.x
  38. Yokoyama T, 1997, CIRCULATION, V95, P1247
  39. Zoccali C, 2002, CIRCULATION, V105, P1354, DOI 10.1161/hc1102.105261

Coleções
Artigos e Materiais de Revistas Científicas - LIM/12
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - ODS/07
Artigos e Materiais de Revistas Científicas - ODS/09
Artigos e Materiais de Revistas Científicas - ODS/12